Lilly Six Sigma: Biotechnology Research and Development Prodcutivity

Lilly invests in research and development productivity in biotechnology to replenish its product pipeline and position the company for accelerated growth and profitability. Six Sigma techniques such as QFD, Voice of the Customer support the front-end of pharmaceutical innovation. Design for Six Sigma, Design of Experiments, DOE, enables research and development. Biotech products already comprise a third of Lilly's product pipeline and target a number of diseases, such as Alzheimers, diabetes, inflammation, and kidney disease. Lilly is striving to commericalize one major biotechnology molecule per year. ...

... "Paul summarized Lilly's R&D productivity efforts by stating, We are pursuing three broad strategic approaches to improving R&D productivity, with the goals of increasing the number of compounds in our pipeline while driving down the costs per new molecular entity by about one-third, from $1.2 billion to $800 million. These productivity strategies include fully leveraging our biotech capabilities, accessing more flexible and cost effective R&D capacity globally and aggressively pursuing Six Sigma throughout Lilly Research Labs. " ...

Via Lilly: Lilly Delivers Promising Update to Wall Street on Strategic Priorities, Pipeline Progress and Earnings Guidance